Nivolumab as the new standard of metastatic kidney cancer treatment

The last decade was marked by the rapid development of kidney cancer drug treatment and advent of targeted drugs aimed at inhibition of angiogenesis which plays a crucial role in tumor growth. Despite certain success, targeted antiangiogenetic therapy with tyrosine kinase inhibitors, mammalian targe...

Full description

Bibliographic Details
Main Author: V. B. Matveev
Format: Article
Language:Russian
Published: ABV-press 2017-10-01
Series:Onkourologiâ
Subjects:
Online Access:https://oncourology.abvpress.ru/oncur/article/view/717